Whilst re-expression of EZH2 has a tumour suppressor effect in myeloid malignancies, it is the depletion of EZH2 in PDAC that is associated with conversion towards the less aggressive, classical molecular subtype [31,148]. The gene discussed is EZH2; the disease is neoplasm.